mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment

Lymphomas represent the seventh most common cancer in developed countries. The vascular nature of the majority of lymphomas represents a favorable situation for immunotherapy. Monoclonal antibodies against main lymphoma markers have been developed over the last three decades and some of them are commonly used in clinics. This chapter focuses on the main monoclonal antibodies directed against CD20 and other lymphoma markers and the results of the main clinical trials are summarized.